ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.732,05
-1,34%
S&P 500
5.844,25
-0,39%
Dow Jones
42.300,10
-0,10%
Euro vs US Dollar
1,03947
0,30%
Bitcoin
95.314,64
-2,20%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Palisade Bio Inc (PALI)

  7. Palisade Bio Inc (PALI) News

PALI

Palisade Bio (PALI)

Palisade Bio Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PALI
DatumZeitQuelleÜberschriftSymbolFirma
17/12/202423h30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PALIPalisade Bio Inc
17/12/202423h29Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PALIPalisade Bio Inc
17/12/202423h29Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PALIPalisade Bio Inc
17/12/202414h30GlobeNewswire Inc.Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory BoardNASDAQ:PALIPalisade Bio Inc
17/12/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PALIPalisade Bio Inc
16/12/202422h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PALIPalisade Bio Inc
13/12/202422h05GlobeNewswire Inc.Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq RulesNASDAQ:PALIPalisade Bio Inc
13/12/202416h31Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PALIPalisade Bio Inc
13/12/202415h57Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PALIPalisade Bio Inc
13/12/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PALIPalisade Bio Inc
12/12/202418h05GlobeNewswire Inc.Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq RulesNASDAQ:PALIPalisade Bio Inc
09/12/202423h30Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:PALIPalisade Bio Inc
05/12/202416h25Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:PALIPalisade Bio Inc
03/12/202414h15GlobeNewswire Inc.Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated SubjectsNASDAQ:PALIPalisade Bio Inc
22/11/202423h10Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:PALIPalisade Bio Inc
22/11/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
22/11/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
21/11/202420h18Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:PALIPalisade Bio Inc
21/11/202414h15GlobeNewswire Inc.Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)NASDAQ:PALIPalisade Bio Inc
14/11/202421h35Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:PALIPalisade Bio Inc
14/11/202415h00GlobeNewswire Inc.Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) SummitNASDAQ:PALIPalisade Bio Inc
12/11/202414h45GlobeNewswire Inc.Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108NASDAQ:PALIPalisade Bio Inc
07/11/202414h30GlobeNewswire Inc.Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)NASDAQ:PALIPalisade Bio Inc
31/10/202413h30GlobeNewswire Inc.Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative ColitisNASDAQ:PALIPalisade Bio Inc
30/10/202411h05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PALIPalisade Bio Inc
15/10/202414h00GlobeNewswire Inc.Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific MeetingNASDAQ:PALIPalisade Bio Inc
10/10/202414h30GlobeNewswire Inc.Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)NASDAQ:PALIPalisade Bio Inc
08/10/202414h00GlobeNewswire Inc.Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCNASDAQ:PALIPalisade Bio Inc
27/09/202422h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PALIPalisade Bio Inc
25/09/202414h00GlobeNewswire Inc.Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative ColitisNASDAQ:PALIPalisade Bio Inc
 Showing the most relevant articles for your search:NASDAQ:PALI

Kürzlich von Ihnen besucht

TG
MBG
MercedesBenz
COIN
BTCUSD
Bitcoin
NASDAQ
TSLA
Tesla
USOTC
RHHBY
Roche (QX)
NYSE
KO
Coca Cola
USOTC
ADDYY
Adidas (QX)
AMEX
XLF
Financial Select Sector
DBI
TDXP
Tec DAX
TG
DBK
Deutsche Bank
NASDAQ
AMZN
Amazon.com
COIN
ETHUSD
Ethereum
NYSE
JPM
JP Morgan Chase
TG
BAYN
Bayer
DBI
DAX
DAX
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten